NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
Símbolo de cotizaciónNEO
Nombre de la empresaNeogenomics Inc
Fecha de salida a bolsaDec 10, 2012
Director ejecutivoMr. Antony P. Zook
Número de empleados2200
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 10
Dirección9490 Neogenomics Way
CiudadFORT MYERS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33912
Teléfono12397680600
Sitio Webhttps://neogenomics.com/
Símbolo de cotizaciónNEO
Fecha de salida a bolsaDec 10, 2012
Director ejecutivoMr. Antony P. Zook
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos